000			03275cam a2200397 i 4500
999			_c115960 _d115960
001			19826536
003			OSt
005			20200220074251.0
008			170724s2018 enk b 001 0 eng
010			_a 2017950105
020			_a9780198803539
040			_aDLC _beng _erda _cDLC
042			_apcc
043			_an-us---
050	0	0	_aKF8925.P7 _bH47 2018
082			_a346.73038 HER
100	1		_aHerrmann, Mark, _eauthor.
245	1	0	_aDrug and device product liability litigation strategy / _cMark Herrmann, David B. Alden, Geoffrey M. Drake.
250			_aSecond edition.
264		1	_aOxford, United Kingdom : _bOxford University Press, _c2018.
300			_alxiii, 406 pages ; _c26 cm.
336			_atext _btxt _2rdacontent
337			_aunmediated _bn _2rdamedia
338			_avolume _bnc _2rdacarrier
504			_aIncludes bibliographical references and index.
505	8		_aMachine generated contents note: -- Acknowledgments -- 1. Introduction -- 2. The FDA's Regulation of Prescription Drugs and Devices -- 3. Pre-litigation Counseling -- 4. Legal Issues & Theories -- 5. Consolidated Proceedings -- 6. Aggregated Proceedings - Class Actions -- 7. Aggregated Proceedings - Multidistrict Litigation -- 8. Fact Discovery -- 9. Expert Retention and Discovery -- 10. Expert Testimony, Rule 702, And Daubert -- 11. Preemption -- 12. The Learned Intermediary Doctrine -- 13. Motions In Limine -- 14. Jury Selection -- 15. The Trial Of A Drug Or Device Case -- Table of Authorities -- Index.
520			_a"Each year, thousands of lawsuits are filed in federal and state courts seeking recovery from manufacturers of pharmaceuticals and medical devices. These lawsuits include individual actions, actions consolidated into multidistrict litigation, and class actions. The litigation occasionally becomes life-threatening for the defendant corporations, and may breed a public relations nightmare, as occurred with Vioxx, breast implants, and fen-phen. Drug & Device Product Liability Litigation Strategy, by Mark Herrmann and David B. Alden, offers assistance to lawyers who practice in this high-stakes, high-profile, and rapidly-evolving area. The book's primary focus is to provide useful practice pointers and overall strategic guidance for attorneys involved in product liability litigation for prescription drugs and medical devices. It will serve as an indispensable guide to handling such a case from pre-litigation through trial. The legal landscape in this important area is expected to shift as the Supreme Court's decisions in Riegel v. Medtronic, Inc. and Wyeth v. Levine are applied, and as the President and Congress address tort reform and other health care issues. Practitioners will need thoughtful, expert advice to navigate these changes"-- _cProvided by publisher.
650		0	_aProducts liability _xMedical instruments and apparatus _zUnited States _xTrial practice.
650		0	_aProducts liability _xDrugs _zUnited States _xTrial practice.
700	1		_aAlden, David B., _eauthor.
700	1		_aDrake, Geoffrey M., _eauthor.
906			_a7 _bcbc _corigcop _d2 _eepcn _f20 _gy-gencatlg
942			_2ddc _cBK